Preventive effects of bitter melon (Momordica charantia) against insulin resistance and diabetes are associated with the inhibition of NF-κB and JNK pathways in high-fat-fed OLETF rats

Journal of Nutritional Biochemistry

Volumn 26, Issue 3, 2015, Pages 234-240

  Yang, Soo Jin ^a   Choi, Jung Mook ^b   Park, Se Eun ^b   Rhee, Eun Jung ^b   Lee, Won Young ^b   Oh, Ki Won ^b   Park, Sung Woo ^b   Park, Cheol Young ^b  

^a Chonnam National University   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Bitter melon; Glucose tolerance; Inflammation; Insulin resistance; Obesity

Indexed keywords

CYTOKINE; FAT; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; MOMORDICA CHARANTIA EXTRACT; PROTEIN KINASE B; SERINE; STRESS ACTIVATED PROTEIN KINASE; THREONINE; TRANSCRIPTION FACTOR RELA; TYROSINE; ANTIDIABETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PLANT EXTRACT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; DIET SUPPLEMENTATION; DIETARY INTAKE; DRUG EFFICACY; ENZYME INHIBITION; EPIDIDYMIS FAT; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; LIVER; MALE; MOMORDICA CHARANTIA; MUSCLE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PROTEIN PHOSPHORYLATION; RAT; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; TREATMENT DURATION; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL NUCLEUS; CHEMISTRY; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENT; FRUIT; IMMUNOLOGY; METABOLISM; OBESITY; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PATHOPHYSIOLOGY; PROTEIN TRANSPORT; SKELETAL MUSCLE; WHITE ADIPOSE TISSUE;

CUCUMIS; MOMORDICA CHARANTIA; RATTUS;

ADIPOSE TISSUE, WHITE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL NUCLEUS; CYTOKINES; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DIETARY SUPPLEMENTS; FRUIT; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIVER; MALE; MAP KINASE SIGNALING SYSTEM; MOMORDICA CHARANTIA; MUSCLE, SKELETAL; NF-KAPPA B; OBESITY; PLANT EXTRACTS; PROTEIN TRANSPORT; RATS, INBRED OLETF;

EID: 84927635080     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2014.10.010     Document Type: Article

References (43)

1. de Luca C., Olefsky J.M. Inflammation and insulin resistance. FEBS Lett 2008, 582:97-105.
2. Shoelson S.E., Lee J., Goldfine A.B. Inflammation and insulin resistance. J Clin Invest 2006, 116:1793-1801.
3. Ota T. Chemokine systems link obesity to insulin resistance. Diabetes Metab J 2013, 37:165-172.
4. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444:860-867.
5. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796-1808.
6. Xu H., Barnes G.T., Yang Q., Tan G., Yang D., Chou C.J., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003, 112:1821-1830.
7. Cao H. Adipocytokines in obesity and metabolic disease. J Endocrinol 2014, 220:T47-T59.
8. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
9. Ohashi K., Shibata R., Murohara T., Ouchi N. Role of anti-inflammatory adipokines in obesity-related diseases. Trends Endocrinol Metab 2014, 10.1016/j.tem.2014.03.009.
10. Li S., Shin H.J., Ding E.L., van Dam R.M. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009, 302:179-188.
11. Ryo M., Nakamura T., Kihara S., Kumada M., Shibazaki S., Takahashi M., et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004, 68:975-981.
12. Xu A., Wang Y., Keshaw H., Xu L.Y., Lam K.S., Cooper G.J. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003, 112:91-100.
13. Maeda N., Shimomura I., Kishida K., Nishizawa H., Matsuda M., Nagaretani H., et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002, 8:731-737.
14. Rosen E.D., Spiegelman B.M. Adipocytes as regulators of energy balance and glucose homeostasis. Nature 2006, 444:847-853.
15. Eckel R.H., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet 2005, 365:1415-1428.
16. Trujillo M.E., Scherer P.E. Adipose tissue-derived factors: impact on health and disease. Endocr Rev 2006, 27:762-778.
17. Lila M.A. From beans to berries and beyond: teamwork between plant chemicals for protection of optimal human health. Ann N Y Acad Sci 2007, 1114:372-380.
18. Balunas M.J., Kinghorn A.D. Drug discovery from medicinal plants. Life Sci 2005, 78:431-441.
19. Schmidt B., Ribnicky D.M., Poulev A., Logendra S., Cefalu W.T., Raskin I. A natural history of botanical therapeutics. Metabolism 2008, 57:S3-S9.
20. Kwatra D., Subramaniam D., Ramamoorthy P., Standing D., Moran E., Velayutham R., et al. Methanolic extracts of bitter melon inhibit colon cancer stem cells by affecting energy homeostasis and autophagy. Evid Based Complement Alternat Med 2013, 2013:702869.
21. Nerurkar P., Ray R.B. Bitter melon: antagonist to cancer. Pharm Res 2010, 27:1049-1053.
22. Habicht S.D., Ludwig C., Yang R.Y., Krawinkel M.B. Momordica charantia and type 2 diabetes: from in vitro to human studies. Curr Diabetes Rev 2014, 10:48-60.
23. Ooi C.P., Yassin Z., Hamid T.A. Momordica charantia for type 2 diabetes mellitus. Cochrane Database Syst Rev 2012, 8:CD007845.
24. Basch E., Gabardi S., Ulbricht C. Bitter melon (Momordica charantia): a review of efficacy and safety. Am J Health Syst Pharm 2003, 60:356-359.
25. Grover J.K., Yadav S.P. Pharmacological actions and potential uses of Momordica charantia: a review. J Ethnopharmacol 2004, 93:123-132.
26. Leatherdale B.A., Panesar R.K., Singh G., Atkins T.W., Bailey C.J., Bignell A.H. Improvement in glucose tolerance due to Momordica charantia (karela). Br Med J (Clin Res Ed) 1981, 282:1823-1824.
27. Chen Q., Chan L.L., Li E.T. Bitter melon (Momordica charantia) reduces adiposity, lowers serum insulin and normalizes glucose tolerance in rats fed a high fat diet. J Nutr 2003, 133:1088-1093.
28. Virdi J., Sivakami S., Shahani S., Suthar A.C., Banavalikar M.M., Biyani M.K. Antihyperglycemic effects of three extracts from Momordica charantia. J Ethnopharmacol 2003, 88:107-111.
29. Platel K., Shurpalekar K.S., Srinivasan K. Influence of bitter gourd (Momordica charantia) on growth and blood constituents in albino rats. Nahrung 1993, 37:156-160.
30. Khanna P., Jain S.C., Panagariya A., Dixit V.P. Hypoglycemic activity of polypeptide-p from a plant source. J Nat Prod 1981, 44:648-655.
31. Bao B., Chen Y.G., Zhang L., Na Xu Y.L., Wang X., Liu J., et al. Momordica charantia (bitter melon) reduces obesity-associated macrophage and mast cell infiltration as well as inflammatory cytokine expression in adipose tissues. PLoS One 2013, 8:e84075.
32. Yang S.J., Choi J.M., Chae S.W., Kim W.J., Park S.E., Rhee E.J., et al. Activation of peroxisome proliferator-activated receptor gamma by rosiglitazone increases sirt6 expression and ameliorates hepatic steatosis in rats. PLoS One 2011, 6:e17057.
33. Pickup J.C., Chusney G.D., Thomas S.M., Burt D. Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci 2000, 67:291-300.
34. Hotamisligil G.S., Arner P., Caro J.F., Atkinson R.L., Spiegelman B.M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995, 95:2409-2415.
35. Hotamisligil G.S., Spiegelman B.M. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994, 43:1271-1278.
36. Sartipy P., Loskutoff D.J. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci U S A 2003, 100:7265-7270.
37. Feinstein R., Kanety H., Papa M.Z., Lunenfeld B., Karasik A. Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem 1993, 268:26055-26058.
38. Senn J.J., Klover P.J., Nowak I.A., Mooney R.A. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 2002, 51:3391-3399.
39. Kaneto H., Nakatani Y., Kawamori D., Miyatsuka T., Matsuoka T.A. Involvement of oxidative stress and the JNK pathway in glucose toxicity. Rev Diabet Stud 2004, 1:165-174.
40. Nakatani Y., Kaneto H., Kawamori D., Hatazaki M., Miyatsuka T., Matsuoka T.A., et al. Modulation of the JNK pathway in liver affects insulin resistance status. J Biol Chem 2004, 279:45803-45809.
41. Liuwantara D., Elliot M., Smith M.W., Yam A.O., Walters S.N., Marino E., et al. Nuclear factor-kappaB regulates beta-cell death: a critical role for A20 in beta-cell protection. Diabetes 2006, 55:2491-2501.
42. Hirosumi J., Tuncman G., Chang L., Gorgun C.Z., Uysal K.T., Maeda K., et al. A central role for JNK in obesity and insulin resistance. Nature 2002, 420:333-336.
43. Kaneto H., Nakatani Y., Miyatsuka T., Kawamori D., Matsuoka T.A., Matsuhisa M., et al. Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. Nat Med 2004, 10:1128-1132.